ALK and non-small cell lung carcinoma: Current therapies for NSCLC patients include tyrosine kinase inhibitors such as erlotinib in the presence of an EGFR mutation, or ALK tyrosine kinase inhibitors, crizotinib, ceritinib, and alectinib against EML4-ALK fusions [36].